Zoetis Inc. $ZTS Shares Sold by Andra AP fonden

Andra AP fonden lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 28.0% during the fourth quarter, HoldingsChannel reports. The fund owned 193,000 shares of the company’s stock after selling 75,200 shares during the period. Andra AP fonden’s holdings in Zoetis were worth $24,283,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Global Wealth Strategies & Associates acquired a new position in Zoetis during the fourth quarter worth $25,000. Lodestone Wealth Management LLC purchased a new stake in Zoetis during the fourth quarter worth $30,000. KERR FINANCIAL PLANNING Corp purchased a new stake in Zoetis during the third quarter worth $31,000. Holos Integrated Wealth LLC purchased a new stake in Zoetis during the fourth quarter worth $32,000. Finally, Elyxium Wealth LLC purchased a new stake in Zoetis during the fourth quarter worth $32,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on ZTS shares. William Blair reiterated an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Morgan Stanley restated an “overweight” rating and issued a $115.00 price objective on shares of Zoetis in a research report on Friday, May 15th. Bank of America upped their price objective on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. BTIG Research restated a “buy” rating and issued a $160.00 price objective on shares of Zoetis in a research report on Thursday, February 26th. Finally, Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Six equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $133.92.

Zoetis Stock Performance

Zoetis stock opened at $81.51 on Friday. The firm has a market capitalization of $34.17 billion, a P/E ratio of 13.52, a PEG ratio of 1.27 and a beta of 0.75. The stock has a fifty day moving average price of $97.70 and a 200 day moving average price of $114.47. Zoetis Inc. has a 52 week low of $72.38 and a 52 week high of $168.83. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). The business had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts anticipate that Zoetis Inc. will post 6.88 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.6%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio is presently 35.16%.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple law firms, including Rosen, Bronstein Gewirtz & Grossman, the Schall Law Firm, DJS Law Group, and others, urged investors to join or lead a class action against Zoetis, keeping litigation risk in focus and potentially weighing on sentiment. Article Title
• Negative Sentiment: The lawsuits allege Zoetis misled investors about weakening veterinarian adoption and prescription trends, which could raise concerns about the company’s underlying growth outlook and create overhang on the stock. Article Title
• Neutral Sentiment: Rosen Law Firm and others reminded shareholders that July 27, 2026 is the lead-plaintiff deadline, but these notices are procedural and do not change Zoetis’ fundamentals by themselves. Article Title
• Neutral Sentiment: Bank of America Securities reportedly maintained a “Hold” rating on Zoetis, which suggests Wall Street remains cautious but not overtly bearish. Article Title

Insider Activity at Zoetis

In other Zoetis news, Director Frank A. Damelio bought 6,650 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the purchase, the director owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This trade represents a 44.91% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Paul Bisaro bought 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The stock was acquired at an average price of $75.88 per share, with a total value of $151,760.00. Following the completion of the purchase, the director directly owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders acquired 11,650 shares of company stock worth $886,384. 0.22% of the stock is currently owned by insiders.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.